Navigation Links
Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
Date:11/21/2008

CLINTON, N.J., Nov. 21 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that it has been named Private Company of the Year by the New Jersey Technology Council (NJTC), a 1,200-member non-profit organization that provides business support, networking opportunities, information and advocacy for technology companies and their leaders. Ikaria earned the award based on criteria including market leadership and unique product/service provision.

"We are delighted that the New Jersey Technology Council has recognized Ikaria for its leadership and innovation in critical care medicine," said Daniel Tasse, President and CEO of Ikaria. "This award is a testament to the hard work and pioneering spirit of our organization to deliver novel treatments for patients with unmet medical needs within the underserved critical care market."

Ikaria was honored at the NJTC Awards Gala on November 20, 2008, an annual black-tie event that attracts over 500 attendees. The NJTC Awards was founded in 1996 to publicly recognize and celebrate some of the most successful companies in the New Jersey technology community.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

1. INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.

For more information on INOmax, including important safety information and full prescribing information, please visit www.inomax.com.

    CONTACTS

    Samina Bari                                  Jason Rando/Jen Saunders
    Ikaria                                       The Ruth Group
    (908) 238-6372                               (646) 536-7025/7011
    samina.bari@ikaria.com                       jrando@theruthgroup.com
                                                 jsaunders@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. American Board of Internal Medicine President Named to Alzheimers Study Group
3. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
4. Pharmaxis Establishes Named Patient Program for Bronchitol
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
7. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
8. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
9. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Medical, Inc. (NASDAQ: CGNT), a medical device company that ... urology market, will release financial results for the fourth ... the market open on Thursday, March 9, 2017. ... and webcast to discuss its financial results the same ... Eastern Time (10:00 a.m. Central Time). Darin Hammers ...
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... 2017 Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet ... der südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von ... an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Congratulations to Head Over Heels’ elite ... 12th. Ms. Esparza qualified into this prestigious status after winning the Vault, ... Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation who ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in Miami Beach to host its Swirl: Miami Wine Tasting Event on March ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
Breaking Medicine News(10 mins):